Barrett esophagus is the metaplastic transformation of normal squamous epithelium in the distal esophagus to intestinal-type columnar epithelium (containing goblet cells) in response to chronic gastroesophageal reflux (GER) injury. It develops in 6-12% of GERD patients. It is the most important premalignant condition for esophageal adenocarcinoma — annual cancer risk is 0.3-0.5% in non-dysplastic Barrett, 6-19% in high-grade dysplasia. Endoscopically, salmon-colored columnar mucosa is seen at the distal esophagus. Classified as short segment (<3 cm) and long segment (≥3 cm). 2-3 times more common in males; obesity, white race, and family history increase risk.
Age Range
30-75
Peak Age
55
Gender
Male predominant
Prevalence
Uncommon
Chronic gastroesophageal reflux exposes the distal esophageal mucosa to repeated acid, pepsin, and bile salt injury. Normal squamous epithelium cannot withstand this chronic damage and transforms to intestinal-type columnar epithelium (metaplasia). This transformation is directed by activation of the CDX2 intestinal transcription factor. The metaplastic epithelium contains goblet cells — mandatory for histological diagnosis. Prolonged inflammation and oxidative stress lead to DNA damage accumulation: the p53 mutation, p16 loss, DNA aneuploidy sequence can lead to dysplasia and then adenocarcinoma. On imaging, Barrett esophagus is usually thin without significant wall thickening — but associated esophagitis, stricture, or nodular mucosa provide detectable clues on CT and barium.
Mesh-like, villous mucosal pattern in the distal esophagus on double-contrast barium. This pattern is different from normal flat squamous mucosa and reflects the surface topography of intestinal metaplasia (Barrett). Particularly prominent in long-segment Barrett.
Reticular (mesh-like, villous) mucosal pattern in the distal esophagus on double-contrast barium. Unlike the smooth surface of normal squamous mucosa, Barrett mucosa shows fine linear elevations (villiform pattern). This pattern is typically observed 3-8 cm proximal to the GEJ.
Report Sentence
Reticular mucosal pattern extending approximately ___ cm proximal to the GEJ in the distal esophagus; consistent with Barrett esophagus.
Smooth, short-segment stricture in the distal esophagus proximal to the GEJ (usually 3-5 cm proximal). While peptic strictures are typically at GEJ level, Barrett-associated stricture is more proximal. This 'high stricture' develops at the squamocolumnar junction at the upper end of the Barrett segment.
Report Sentence
Smooth short-segment stricture in the distal esophagus proximal to the GEJ; suggestive of Barrett-associated stricture.
Mild wall thickening and hiatal hernia in the distal esophagus. Thickening is usually mild (5-10 mm) and circumferential. Associated esophagitis findings (submucosal edema, target sign) may be seen. Marked asymmetric thickening or mass suggests adenocarcinoma development.
Report Sentence
Mild circumferential wall thickening in the distal esophagus with hiatal hernia; consistent with chronic reflux esophagitis/Barrett esophagus.
Nodular mucosal pattern or small polypoid projections within the Barrett segment suggest dysplasia or early adenocarcinoma development. Nodular areas show irregular barium retention. This finding is an indication for urgent endoscopic biopsy.
Report Sentence
Nodular mucosal changes in the Barrett segment are seen; urgent endoscopic biopsy is recommended for suspicion of dysplasia/early adenocarcinoma.
Detection of an enhancing nodular lesion or focal asymmetric wall thickening within the Barrett segment favors early adenocarcinoma or high-grade dysplasia. The lesion is usually small (<2 cm) and shows focal enhancement.
Report Sentence
Focal enhancing nodular lesion/wall thickening within the Barrett segment of the distal esophagus; high-grade dysplasia/early adenocarcinoma should be excluded.
Mild thickening and submucosal edema (hyperintense signal) of the distal esophageal wall on T2-weighted sequences. MRI also shows hiatal hernia and GER findings. MRI is not specific for Barrett esophagus diagnosis but can be valuable for complications (stricture, early carcinoma).
Report Sentence
Mild thickening and submucosal edema on T2 in the distal esophageal wall; consistent with chronic reflux/Barrett.
Criteria
Columnar mucosa length <3 cm. Most common type.
Distinct Features
Lower adenocarcinoma risk. Difficult to detect on barium. Endoscopy needed.
Criteria
Columnar mucosa length ≥3 cm.
Distinct Features
Higher adenocarcinoma risk. Reticular pattern more prominent on barium. Closer surveillance.
Criteria
Barrett with histologically confirmed low-grade dysplasia.
Distinct Features
Annual adenocarcinoma risk 0.5-1%. Cannot be radiologically distinguished. 6-12 monthly endoscopic surveillance.
Criteria
Barrett with histologically confirmed high-grade dysplasia. Equivalent to carcinoma in situ.
Distinct Features
Nodular mucosa or focal increased enhancement may be seen. Endoscopic eradication therapy (RFA, EMR) applied. Annual 6-19% cancer risk.
Distinguishing Feature
Esophagitis shows diffuse mucosal irregularity and granular pattern; Barrett shows specific reticular villous pattern with distal localization
Distinguishing Feature
Adenocarcinoma shows marked asymmetric wall thickening, mass, and lymphadenopathy; Barrett has normal or mildly increased wall thickness without mass
Distinguishing Feature
Peptic stricture at GEJ level; Barrett stricture more proximal (squamocolumnar junction). Barrett accompanied by reticular pattern
Distinguishing Feature
Achalasia shows diffuse esophageal dilation and bird-beak sign; Barrett has mucosal changes in distal segment with hiatal hernia
Urgency
surveillanceManagement
surveillanceBiopsy
NeededFollow-up
annualHistopathological confirmation (goblet cells) with endoscopic biopsy is mandatory. Surveillance endoscopy every 3-5 years recommended for non-dysplastic Barrett. For low-grade dysplasia, 6-12 monthly surveillance or endoscopic eradication therapy (RFA). For high-grade dysplasia, endoscopic eradication therapy (RFA, endoscopic mucosal resection, or endoscopic submucosal dissection) is standard. PPI therapy is applied for reflux control and symptom management.
Barrett esophagus is a premalignant condition. If no dysplasia, endoscopic surveillance every 3-5 years; low-grade dysplasia every 6-12 months. High-grade dysplasia requires endoscopic ablation (RFA) or endoscopic mucosal resection.